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Abstract: Inhibitors of human NAD
+-dependent protein deacetylases possess great value for 
  deciphering the biology of these enzymes and as potential therapeutics for metabolic and age-
  related diseases and cancer. In the current study, we have experimentally demonstrated that, the 
  potent  inhibition we obtained previously for one of these enzymes (i.e. sirtuin type 1 (SIRT1)) 
  by simply replacing N
ε-thioacetyl-lysine for N
ε-acetyl-lysine in its peptide substrate, 
  represented a general and efficient strategy to develop potent and selective inhibitors of human 
 NAD
+-dependent protein deacetylase enzymes. Indeed, by using this simple inhibition 
  strategy, potent (low-micromolar) and selective (≤40-fold) SIRT2 and SIRT3 inhibitors, which 
  were either comparable or superior to currently existing inhibitors, have also been quickly 
  identified in the current study. These inhibitors could be used as chemical biological tools or as 
  lead compounds for further focused structure-activity optimization.  
  Keywords: N
ε-thioacetyl-lysine, NAD
+-dependent protein deacetylase, inhibition. 
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1. Introduction  
Reversible lysine N
ε-acetylation on proteins has been increasingly recognized to play critical roles 
in regulating multiple pivotal cellular processes such as gene transcription, cell-cycle progression, and 
metabolism [1-13]. This reversible lysine N
ε-acetylation is coordinated by protein acetyltransferases 
and protein deacetylases (Figure 1). As such, chemical modulation of these enzymes could offer 
therapeutic benefits for treating human diseases including metabolic and age-related diseases and 
cancer. This modulation could also be a chemical biological approach to further deciphering the 
biology of these enzymes.  
 
N
H
HN
H3C
O
H
O
Acetylated protein
N
H
H3N
H
O
Deacetylated protein
Protein
deacetylases
Protein acetyl-
transferases
 
 
Figure 1. The lysine N
ε-acetylation and deacetylation reactions catalyzed 
respectively by protein acetyltransferases and protein deacetylases.  
 
  Human protein deacetylases have been categorized into class I, II, III, and IV subfamilies [6, 
14, 15]. Class I, II, and IV (also collectively known as classical) enzymes include the 11 HDACs, i.e. 
HDAC1-11 (HDAC is the abbreviation for histone deacetylase that is named after the first discovered 
protein substrate histone), and they all require a catalytic zinc (Zn
2+). Class III enzymes include the 7 
human sirtuins, i.e. SIRT1-7 (sirtuin type 1-7). However, among the 7 human sirtuins, only SIRT1, 
SIRT2, SIRT3, and SIRT5 have been demonstrated to be bona fide protein deacetylases, and they all 
require coenzyme nicotinamide adenine dinucleotide (NAD
+) for activity. SIRT4 and SIRT6 are ADP-
ribosyltransferases, whereas an enzymatic activity for SIRT7 has not been identified.  
As compared to the long-standing active pursuit of inhibitors of Zn
2+-dependent classical enzymes, 
the development of inhibitors/activators of the NAD
+-dependent protein deacetylases has only gained 
pace recently [8-13]. Regarding the inhibitor development for these latter enzymes, up to this date, 
there have been only two research reports disclosing the discovery of not only potent but also selective 
inhibitors, i.e. an indole-based SIRT1 inhibitor (IC50 ~98 nM) reported by Napper, et al. [16] and a 
SIRT2 inhibitor (IC50 ~3.5 μM) reported by Outeiro, et al. [17]. Weak (micromolar level) and/or non-
selective (inhibiting multiple deacetylases within the class III subfamily and/or also inhibiting 
enzymes outside of this subfamily) inhibition was observed for all the other currently reported 
inhibitors whose potency and selectivity have been sufficiently addressed. Therefore, developing novel 
inhibition strategies and inhibitors for human NAD
+-dependent protein deacetylases is expected to 
constitute an active research area in years to come. 
By evaluating human p53 tumor suppressor protein C-terminal peptides (amino acid residues 372-
389) containing N
ε-thioacetyl-lysine (peptide 1a) or N
ε-acetyl-lysine (Peptide 1b) at the 382 position Int. J. Mol. Sci. 2008, 9                           
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(Figure 2), we previously demonstrated that, whereas the two peptides were comparably 
de(thio)acetylated by HDAC8, peptide 1a was a potent inhibitor for SIRT1 with an IC50 ~2 μM [18], 
only secondary to the indole-based SIRT1 inhibitor reported by Napper, et al. [16]. Our previous 
experimental data further suggested that the observed potent SIRT1 inhibition by peptide 1a could be 
conferred by its processing by SIRT1, but with the formation of a longer-lived catalytically less 
competent intermediate following the nicotinamide cleavage step, as compared to the normal 
processing of peptide 1b by SIRT1 [18]. Because the catalytic domains were predicted to be highly 
conserved among the four currently known human NAD
+-dependent protein deacetylases, i.e. SIRT1, 
SIRT2, SIRT3, and SIRT5 [14, 15, 19], we hypothesized that the potent SIRT1 inhibition by peptide 
1a has defined a simple yet general and effective inhibition strategy for all human NAD
+-dependent 
protein deacetylases, i.e. the transformation of peptide substrates to potent peptide inhibitors by simple 
replacement of N
ε-thioacetyl-lysine for N
ε-acetyl-lysine. Because physiological substrates have been 
identified for SIRT1, SIRT2, and SIRT3, but not yet for SIRT5 [6], we chose SIRT2 and SIRT3 to test 
our hypothesis. 
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Peptide 1a: H2N-KKGQSTSRHK(ThAcK)LMFKTEG-COOH 
Peptide 1b: H2N-KKGQSTSRHK(AcK)LMFKTEG-COOH 
Peptide 1c: H2N-KKGQSTSRHK(K)LMFKTEG-COOH 
Peptide 2: H2N-MPSD(ThAcK)TIGG-COOH
Peptide 3a: H2N-KRLPKTRSG(ThAcK)VMRRLLRKII-COOH
Peptide 3b: H2N-KRLPKTRSG(AcK)VMRRLLRKII-COOH
Peptide 3c: H2N-KRLPKTRSG(K)VMRRLLRKII-COOH
 
 
Figure 2. Peptides used in the current study. The following peptide templates were used:  
Peptides 1a-c, SIRT1 substrate human p53 tumor suppressor protein (372-389) [18];  
Peptide 2, SIRT2 substrate human α-tubulin (36-44); Peptides 3a-c, SIRT3  
substrate human Acetyl-coenzyme A synthetase 2 (AceCS2) (633-652). 
2. Results and Discussion 
2.1 Peptide-based potent and selective inhibitors of SIRT1, SIRT2, and SIRT3 
 
Figure 2 shows the amino acid sequences for all the peptides that were used in the current study. 
These peptides include peptides 1a-c that were also used previously by us [18, 20] and others [21-23] 
for various studies; peptide 2 that was based on the template derived from the SIRT2 substrate human 
α-tubulin; and peptides 3a-c that were based on the template derived from the SIRT3 substrate human 
AceCS2. Fmoc-chemistry-based strategy was employed for solid phase peptide synthesis [24], and N
α-
Fmoc-N
ε-thioacetyl-lysine [18] was used to incorporate N
ε-thioacetyl-lysine into peptides.  
Peptides  1b and 1c were used, respectively, as the substrate and the synthetic authentic 
deacetylation peptide product for the SIRT1 inhibition assay based on high pressure liquid 
chromatography (HPLC) [18]. Peptides 3b and 3c were used, respectively, as the substrate and the 
synthetic authentic deacetylation peptide product for the HPLC-based SIRT3 inhibition assay. Peptide Int. J. Mol. Sci. 2008, 9                           
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1b was also employed as an in vitro substrate in our HPLC-based SIRT2 inhibition assay because we 
found that, albeit being ~8-fold less efficiently processed by SIRT2 as compared to by SIRT1, peptide 
1b still gave rise to reliable signal when longer reaction times were used. 
All the inhibition assays with SIRT1, SIRT2, and SIRT3 were performed under initial conditions 
(turnover of the limiting substrate was maintained at ≤12%) (see Experimental Section). Linear Dixon 
plots (1/v0 vs. [inhibitor]) were obtained from all the assay data, and were used to estimate IC50 values 
as an indication of the inhibition potency (Table 1). 
 
Table 1. Human sirtuin inhibitor evaluation
a 
 
Peptide IC50 (μM)
b HDAC8 
SIRT1 SIRT2 SIRT3 
1a  1.7 ± 0.4
c  1.8 ± 0.3  67.3 ± 2.4  +
c,d 
2  116.8 ± 12.0  11.4 ± 1.1  449.4 ± 18.4  –
e 
3a  0.9 ± 0.2  4.3 ± 0.3  4.5 ± 2.0  – 
  aSubstrate concentrations used in an inhibition assay: 0.5 mM β-NAD
+, 0.3 mM  
peptide substrate. 
bMean ± standard deviation of duplicate measurements. 
cAlso  
see Ref. 18.
 dSensitive to HDAC8. 
eResistant to HDAC8. 
 
It is apparent from Table 1 that peptides 2 and 3a also turned out to be potent inhibitors for SIRT2 
(IC50 ~11 μM) and SIRT3 (IC50 ~5 μM), respectively. Indeed, peptide 3a represented the very first 
potent SIRT3 inhibitor ever identified. These data strongly supported our hypothesis that the potent 
SIRT1 inhibition by peptide 1a has defined a simple yet general and effective inhibition strategy for all 
human NAD
+-dependent protein deacetylases, i.e. the transformation of peptide substrates to potent 
peptide inhibitors by simple replacement of N
ε-thioacetyl-lysine for N
ε-acetyl-lysine. 
Peptides 1a, 2, and 3a were further evaluated for their possible selective inhibition among SIRT1, 
SIRT2, and SIRT3. As shown in Table 1: i) peptide 1a was found to have a comparable inhibition 
potency against SIRT2 to that against SIRT1, but a ~35-fold weaker inhibition potency against SIRT3; 
ii) peptide 2 was found to be a ~10-fold and ~40-fold weaker inhibitor for SIRT1 and SIRT3, 
respectively, as compared to its inhibition against SIRT2; iii) peptide 3a was found to be a comparably 
potent inhibitor for both SIRT2 and SIRT3, but a ~5-fold stronger inhibitor for SIRT1. The rationale 
behind our decision to evaluate the relative inhibition potencies of peptides 1a, 2, and 3a  among 
SIRT1, SIRT2, and SIRT3 was that, if the amino acid residues surrounding the “warhead” (i.e. N
ε-
thioacetyl-lysine) in these peptides defined different “addresses” that were to be recognized by 
different enzymes, selective inhibition ought to be obtained. That we indeed observed different degrees 
of selective inhibition supported this rationale. However, several findings in our current study need 
further discussion, most notably the strong inhibition of peptide 1a against SIRT2 and peptide 3a 
against both SIRT1 and SIRT2 (Table 1), because peptides 1a and 3a were based on peptide templates 
derived from the SIRT1 physiological substrate human p53 protein and the SIRT3 physiological 
substrate human AceCS2, respectively. These results could imply that, under certain in vivo 
conditions, SIRT2 could also accept human p53 protein and AceCS2 as its substrates and SIRT1 could Int. J. Mol. Sci. 2008, 9                           
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also accept AceCS2 as its substrate. Alternatively, these in vitro experimental data with purified 
recombinant enzymes may not fully account for the substrate selection by these enzymes in vivo, 
which could also be regulated by both spatial and temporal mechanisms. 
2.2 Possible HDAC8-catalyzed dethioacetylation of peptide-based inhibitors    
Our previous demonstration that peptides 1a and 1b were comparably de(thio)acetylated by 
HDAC8 [18] suggested that, when placed within an appropriate amino acid sequence, the thioacetyl 
group can serve as a functional mimic for the acetyl group for the enzymatic deacetylation reaction 
catalyzed by HDAC8. In a subsequent set of experiments employing the HeLa nuclear extracts 
enriched in HDAC1 and HDAC2 as well as the purified recombinant HDAC1 and HDAC2 as enzyme 
preparations, we previously further demonstrated that the replacement of N
ε-thioacetyl-lysine for N
ε-
acetyl-lysine conferred resistance to HDACs other than HDAC8 [25]. Taken together, these previous 
experimental results argued for the notion that, when placed within an appropriate amino acid 
sequence, the thioacetyl group can serve as a functional mimic for the acetyl group only for HDAC8-
catalyzed reaction. Therefore, in the current study, we sought to determine if peptides 2 and 3a could 
also be dethioacetylated by HDAC8, because the lability of a N
ε-thioacetyl-lysine-containing peptide 
toward HDAC8 is expected to diminish its value as a chemical biological research tool or a potential 
therapeutic agent.  
In a HPLC-based HDAC8 assay [18, 20], peptides 1b, 2, and 3a were allowed to be incubated for 2 
h at room temperature in the HDAC8 assay buffer. While ~10% substrate turnover from peptide 1b 
was observed, no detectable formation of the dethioacetylated peptide products was observed from 
both peptides 2 and 3a (Figure 3), indicating that, unlike peptides 1a and 1b, peptides 2 and 3a could 
not be dethioacetylated by HDAC8 under the same experimental conditions.  
Taken together with section 2.1, we have experimentally demonstrated that, the potent inhibition we 
obtained previously for SIRT1 by simply replacing N
ε-thioacetyl-lysine for N
ε-acetyl-lysine in its 
peptide substrate, represented a general and efficient strategy to develop potent and selective inhibitors 
of human NAD
+-dependent protein deacetylase enzymes. Furthermore, we have identified a potent and 
selective SIRT2 inhibitor (peptide 2) and a potent pan-sirtuin (among SIRT1, SIRT2, and SIRT3) 
inhibitor (peptide 3a)  that showed resistance to enzymatic dethioacetylation by classical HDAC 
enzymes. Peptides 2 and 3a will thus be expected to be valuable as chemical tools for deciphering the 
biology of these human sirtuins. Even though these peptide-based inhibitors might not be cell 
permeable, they could be ferried inside a cell by their conjugation (e.g. via a disulfide linkage) to 
various types of protein transduction domain (PTD) peptides [26-30]. Once a PTD peptide carries an 
inhibitor as cargo across cellular membranes, the cargo can be released inside a cell (e.g. following the 
cleavage of a disulfide linkage due to a reductive intracellular environment). Peptides 2 and 3a shall 
also be valuable lead compounds for developing inhibitors with enhanced potency, selectivity, 
metabolic stability, and cellular membrane permeability. Toward this goal of developing improved 
inhibitors suitable for in vivo applications, the following stepwise strategy could be considered. i) To 
obtain structurally more manageable minimal peptide sequences via peptide truncation. The feasibility 
of peptide sequence truncation without drastic loss of inhibition potency could be supported by the 
following studies [31, 32]: a) a previous X-ray structural analysis of a sirtuin enzyme with peptide 1b  
 Int. J. Mol. Sci. 2008, 9                           
           
 
6
     
                            20                          25                           30                          35                           40   
                     tR / min 
 
      
                                    20                          25                          30                          35                           40  
                       tR / min 
                                        
      
                20                           25                           30                          35                           40   
                     tR / min 
 
Figure 3. Representative HPLC chromatograms from HDAC8 assays with peptides 1b, 2, and 3a. All 
assays were performed in duplicate and essentially the same HPLC chromatograms were obtained for 
duplicates. The small peak with tR~27 min in the second chromatogram was from a minor impurity in 
the purified peptide 2 sample, rather than the dethioacetylated product. The lack of detectable 
dethioacetylation of peptide 3a was apparent from the absence of a peak with tR~34 min (for peptide 
3c) in the third chromatogram. 
 
showed that N
ε-acetyl-lysine and the two amino acid residues on each side of N
ε-acetyl-lysine were 
the peptide residues that made predominant binding interactions with the sirtuin enzyme used; b) 
multiple 5-mer peptides harboring N
ε-acetyl-lysine in their middle positions were identified from a 
combinatorial peptide library to serve as good SIRT1 substrates. This feasibility was further directly 
supported by our observed modest decrease (ca. 6-fold) in inhibition potency following truncation of 
the 18-mer peptide 1a to a 5-mer peptide (i.e. H2N-HK(ThAcK)LM-COOH) (Fatkins and Zheng, 
unpublished results). ii) To construct and screen (against various human sirtuins) a focused peptide 
library in which all the library members will have N
ε-thioacetyl-lysine occupying their middle 
positions. iii) To perform further medicinal chemistry manipulations on library hits. While maintaining 
the potency and selectivity of hits, their metabolic stability and cellular membrane permeability could 
be potentially enhanced through the minimization of their peptidic nature.  
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3. Experimental Section 
 
3.1 Peptide synthesis and purification 
 
All peptides were synthesized based on the Fmoc chemistry strategy on a PS3 peptide synthesizer 
(Protein Technologies Inc., Tucson, AZ, USA). Except N
α-Fmoc-N
ε-thioacetyl-lysine, all other Fmoc-
protected amino acids and pre-loaded Wang resins were purchased from Novabiochem
 (La Jolla, CA, 
USA). N
α-Fmoc-N
ε-thioacetyl-lysine was synthesized from N
α-Fmoc-lysine and ethyl dithioacetate as 
described previously [18]. For each coupling reaction, 4 equivalents of a Fmoc-protected amino acid, 
3.8-4.0 equivalents of the coupling reagent 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
hexafluorophosphate (HBTU) and the additive N-hydroxybenzotriazole (HOBt) were used in the 
presence of 0.4 M 4-methylmorpholine (NMM)/DMF, and the coupling reaction was allowed to 
proceed at room temperature for 1 h. A 20% (v/v) piperidine/DMF solution was used for Fmoc 
removal. All the peptides were cleaved from the resins by reagent K (83.6% (v/v) trifluoroacetic acid, 
5.9% (v/v) phenol, 4.2% (v/v) double-deionized water (ddH2O), 4.2% (v/v) thioanisole, 2.1% (v/v) 
ethanedithiol), precipitated in cold diethyl ether, and purified by reversed-phase HPLC on a 
preparative C18 column (100 Å, 2.14 x 25 cm). The column was eluted with a gradient of ddH2O 
containing 0.05% (v/v) of trifluoroacetic acid and acetonitrile containing 0.05% (v/v) of trifluoroacetic 
acid at 10 mL/min and monitored at 214 nm. The pooled HPLC fractions were stripped of acetonitrile 
and lyophilized to give all peptides as puffy white solids. Peptide purity (>95%) was verified by 
reversed-phase HPLC on an analytical C18 column (100 Å, 0.46 x 25 cm). The column was eluted 
with a gradient of ddH2O containing 0.05% (v/v) of trifluoroacetic acid and acetonitrile containing 
0.05% (v/v) of trifluoroacetic acid at 1 mL/min and monitored at 214 nm. The molecular weights of all 
purified peptides were confirmed by matrix assisted laser desorption ionization-time of flight 
(MALDI-TOF) mass spectrometric analysis. Peptide 1a: 2149 [M+H]
+; Peptide 1b: 2133 [M+H]
+; 
Peptide  1c: 2091 [M+H]
+; Peptide 2: 964 [M+H]
+; Peptide 3a: 2508 [M+H]
+; Peptide 3b: 2492 
[M+H]
+; Peptide 3c: 2450 [M+H]
+.   
 
3.2 Inhibition assays with recombinant SIRT1, SIRT2, and SIRT3 
 
  GST-SIRT1 (whose plasmid is a kind gift from Prof. Tony Kouzarides) that we expressed and 
purified from Escherichia coli according to literature protocols [33-35] was used for SIRT1 inhibition 
assay since we have previously demonstrated the comparable activities of GST-free SIRT1 and GST-
SIRT1 toward both peptides 1a and 1b [18]. For SIRT2 and SIRT3 inhibition assays, we used the tag-
free SIRT2 (Cat. # SE251-0500) and the tag-free SIRT3 (Cat. #SE270-0500) from BIOMOL 
International L.P. (Plymouth Meeting, PA, USA). Essentially the same procedures were used for the 
inhibition assays with SIRT1, SIRT2, and SIRT3 enzymes, and were performed as described 
previously for the HPLC-based SIRT1 assay [18, 20]. In brief, an inhibition assay solution had the 
following components: 25 mM (or 50 mM for SIRT2 assay) Tris•HCl (pH 8.0), 137 mM NaCl, 2.7 
mM KCl, 1 mM MgCl2, 1 mg/mL BSA (SIGMA Cat. #A3803 with reduced fatty acid content, for 
SIRT2 assay only), 0.5 mM β-NAD
+, 0.3 mM peptide substrate (peptide 1b for SIRT1 and SIRT2 
assays; peptide 3b for SIRT3 assay), an inhibitor (peptide 1a, 2, or 3a) with varied concentrations Int. J. Mol. Sci. 2008, 9                           
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including 0, and an enzyme (GST-SIRT1, 0.15 μM; SIRT2, 0.3 μM; or SIRT3, 2.0 μM). An enzymatic 
reaction was initiated by the addition of an enzyme at 37 °C and was allowed to be incubated at 37 °C 
for 10 min (for SIRT1 assay) or 60 min (for SIRT2 and SIRT3 assays) until quenched with the 
following stop solution: 100 mM HCl and 0.16 M acetic acid. Turnover of the limiting substrate was 
maintained at ≤12%. The quenched assay solutions were directly injected into a reversed-phase HPLC 
C18 column (100 Å, 0.46 x 25 cm), eluting with the following gradients of ddH2O containing 0.05% 
(v/v) trifluoroacetic acid (mobile phase A) and acetonitrile containing 0.05% (v/v) trifluoroacetic acid 
(mobile phase B): linear increase from 0% B to 35% B (for SIRT1 assay) or 40% B (for SIRT2 and 
SIRT3 assays) from 0–40 min (1 mL/min), and UV monitoring at 214 nm. The enzymatic 
deacetylation products (peptide 1c in SIRT1 and SIRT2 assays; peptide 3c in SIRT3 assay) were 
confirmed by their comigration with the chemically synthesized authentic samples and by MALDI-
TOF mass spectrometric analysis, and were quantified by HPLC peak integration and comparison with 
those of synthetic authentic samples. Under the same assay conditions, no detectable formation of the 
deacetylation products (i.e. peptides 1c and 3c) was observed for non-enzymatic reactions. 
Furthermore, under the same assay conditions, peptides 1a and 3a did not give rise to detectable 
formation of peptides 1c and 3c, respectively, via dethioacetylation. No detectable formation of the 
corresponding dethioacetylated peptide from peptide 2 was also observed under the same assay 
conditions. All peptide stock solutions were prepared in ddH2O. IC50 values were estimated from 
Dixon plots (1/v0 vs. [inhibitor]) [36] as an indication of the inhibition potency. 
 
3.3 Assay with recombinant HDAC8 
 
  The recombinant HDAC8 (Cat. #SE145-0100) was purchased from BIOMOL International 
L.P. (Plymouth Meeting, PA, USA). The HPLC-based HDAC8 assay was performed as previously 
described [18, 20]. In brief, a HDAC8 assay solution had the following components: 25 mM Tris•HCl 
(pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1 mg/mL BSA (SIGMA Cat. #A3803 with 
reduced fatty acid content), 0.3 mM peptide 1b, 2, or 3a, and 1.5 μM HDAC8. An enzymatic reaction 
was initiated by the addition of HDAC8 at room temperature and was allowed to be incubated at room 
temperature for 2 h before quenched with the following stop solution: 1.0 M HCl and 0.16 M acetic 
acid. The quenched assay solutions were directly injected into a reversed-phase HPLC C18 column 
(100 Å, 0.46 x 25 cm),  eluting with the following gradients of ddH2O containing 0.05% (v/v) 
trifluoroacetic acid (mobile phase A) and acetonitrile containing 0.05% (v/v) trifluoroacetic acid 
(mobile phase B): linear increase from 0% B to 35% B (for the assay with peptide 2 or 1b) or 40% B 
(for the assay with peptide 3a or 1b) from 0–40 min (1 mL/min), and UV monitoring at 214 nm. Under 
the HDAC8 assay conditions, the deacetylated peptide (i.e. peptide 1c) was formed from peptide 1b as 
we observed previously [18, 20], however, no detectable formation of the corresponding 
dethioacetylated peptides from peptides 2 and 3a was observed. The enzymatically formed peptide 1c 
was confirmed by its comigration with the chemically synthesized authentic sample and by MALDI-
TOF mass spectrometric analysis, and was quantified by HPLC peak integration and comparison with 
that of synthetic authentic sample. Under the same assay conditions, no detectable formation of peptide 
1c was observed for non-enzymatic reactions. 
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4. Conclusions 
 
In the current study, we have experimentally demonstrated that, the potent inhibition we obtained 
previously for SIRT1 by simply replacing N
ε-thioacetyl-lysine for N
ε-acetyl-lysine in its peptide 
substrate, represented a general and efficient strategy to develop potent and selective inhibitors of 
human NAD
+-dependent protein deacetylase enzymes. Due to their resistance to enzymatic 
dethioacetylation by classical HDAC enzymes, the potent and selective SIRT2 inhibitor peptide 2 and 
the potent pan-sirtuin (among SIRT1, SIRT2, and SIRT3) inhibitor peptide 3a identified in the current 
study will be expected to be valuable as chemical tools for deciphering the biology of these human 
sirtuins. The availability of various types of PTD peptides [26-30] should promote the cellular 
applications of these peptide-based inhibitors by carrying them through cellular membranes. 
Furthermore, peptides 2 and 3a shall be valuable lead compounds for further focused structure-activity 
optimization. 
Acknowledgements 
We thank the James L. and Martha J. Foght Endowment, the University of Akron Research 
Foundation, and the University of Akron Faculty Research Fellowship for financial support. We thank 
Prof. Tony Kouzarides (University of Cambridge, UK) for the GST-SIRT1 plasmid, and Prof. Chrys 
Wesdemiotis and his research group at the University of Akron for the assistance with mass 
spectrometric analysis for the peptides used in the current study. 
Notes Added in Proof 
When this manuscript was under review, Smith, et al. described a detailed mechanistic study of the 
potent inhibition of a N
ε-thioacetyl-lysine-containing human histone H3 peptide (H2N-
KSTGGKXAPRKQ-OH, wherein X is N
ε-thioacetyl-lysine) against Hst2, a yeast sirtuin enzyme [37]. 
Their conclusion that this histone H3 peptide behaved as a mechanism-based inhibitor agreed with our 
previous mechanistic suggestion that the observed potent SIRT1 inhibition by peptide 1a could be 
conferred by its processing by SIRT1, but with the formation of a longer-lived catalytically less 
competent intermediate following the nicotinamide cleavage step, as compared to the normal 
processing of peptide 1b by SIRT1 [18]. In their paper [37], Smith, et al. also described their discovery 
that the above histone H3 peptide behaved as a potent inhibitor against SIRT1, SIRT2, and SIRT3 with 
respective IC50 values being 2.0 ± 0.2 μM, 5.6 ± 0.8 μM, and 2.3 ± 0.3 μM, when assayed against the 
sirtuin-catalyzed deacetylation of a 
3H-acetylated histone H3 peptide substrate. However, whether or 
not their inhibitor could be dethioacetylated by HDAC8 was not examined. 
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